Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01202942 · ClinicalTrials.gov registry record · NA
Use and Harm Exposure in New Low Nicotine Cigarettes
A NA study of Cigarette Smoking, sponsored by University of Pennsylvania.
- Completed
- Registry status
- NA
- Development phase
- 246
- Enrollment target
- 1
- Study location
NCT01202942: Completed NA study of Cigarette Smoking, sponsored by University of Pennsylvania.
NCT01202942 is a NA study of Cigarette Smoking that has completed, run by University of Pennsylvania. The registered enrollment target is 246 participants, above the 171-participant average among 45 other Cigarette Smoking trials with a reported enrollment target (44% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01202942, a NA study of Cigarette Smoking, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- NA
- Development phase
- 246 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed research extends previous research on Quest® cigarette smoking behavior by testing whether compensatory smoking occurs as cigarette nicotine level decreases, and whether, as a result, biomarkers of harm exposure increase. This hypothesis will be tested in 210 smokers who report smoking at least 15 cigarettes per day and have been smoking for at least five years and are not currently interested in quitting, but interested in trying a new cigarette product. Participants will be randomized to one of three conditions: 1) smoke their own preferred brand (control group); 2) smoke Quest® cigarettes in progressively decreasing cigarette nicotine level (step-down); or 3) Quest® cigarette non-step-down condition, where they will smoke Quest® cigarettes in a random order. The study will consist of 4 stages beginning with a 5-day preferred own brand cigarette smoking phase for all participants, followed by one of the three cigarette conditions. For those smoking Quest® cigarettes, cigarette nicotine level will change every 10 days, either in a step-down or random fashion. The primary behavioral outcome is smoking topography, a quantitative measurement of smoke exposure. Alveolar carbon monoxide (CO), a validated assessment of smoke exposure, and urine samples to assess carcinogen exposure, specifically NNAL (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol) and 1-HOP (1-hydroxypyrere), and exhaled breath condensate will also be collected at the laboratory visits. At the initiation of the study, participants will view the Quest® print advertisement and complete a survey related to product expectations in order to determine the impact marketing and advertisement has on beliefs, attitudes and behaviors related to Quest® cigarettes.
Conditions Studied
Interventions
- OTHER Quest
Study Locations (1)
Pennsylvania
- Tobacco Use Research Center, UPenn - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 246 participants |
| Start Date | 2007-07 |
| Est. Completion | 2013-06 |
| Phase | NA |
What the finished NCT01202942 record still lists
NCT01202942 is an interventional study that assigns participants to a tested intervention. The registered 246 participants enrollment target is mid-sized for trials with a published cap, above the 171-participant average among 45 other Cigarette Smoking trials with a reported enrollment target (44% higher).
The record links to 1 condition, with Cigarette Smoking appearing as the primary indexed condition, and to 1 intervention - of which Quest is the first listed.
NCT01202942 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01202942 about?
NCT01202942 is a clinical study titled "Use and Harm Exposure in New Low Nicotine Cigarettes". The proposed research extends previous research on Quest® cigarette smoking behavior by testing whether compensatory smoking occurs as cigarette nicotine level decreases, and whether, as a result, biomarkers of harm exposure increase. This hypothesis will be tested in 210 smokers who report smoking ...
What is the current status of trial NCT01202942?
This trial is currently completed. It is a NA study. The enrollment target is 246 participants. The study started on 2007-07. Estimated completion is 2013-06.
What conditions does trial NCT01202942 study?
This clinical trial studies the following conditions: Cigarette Smoking.
What interventions are being tested in trial NCT01202942?
The interventions under investigation include: Quest (OTHER).
Who is sponsoring clinical trial NCT01202942?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01202942 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cigarette Smoking
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01202942's enrollment target sits among peer trials
246 9th of 45 higher than 37 of 45 other Cigarette Smoking trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cigarette Smoking trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effects of Tax Proposals and Cigarette Availability on Tobacco Purchasing
RECRUITING · NA
-
Menthol, Inflammation, and Nicotine Transition Study
RECRUITING · NA
-
RTMS Targets Neural Circuits for Smoking Cessation
RECRUITING · NA
-
Development of a Mobile Health Intervention for Electronic Cigarette Use Among Young Adults
RECRUITING · NA
-
Catalyzing Cigarette Smoking Cessation Through Harm Reduction Sampling Among People Unmotivated to Quit
RECRUITING · NA
-
A Clinical Trial of Adaptive Treatment for Early Smoking Cessation Relapse
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04973605 · 246 participants · Phase 1
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- NCT06395168 · 246 participants · NA
Mayo Clinic Health System Northwest Wisconsin Integrated Maternal Postpartum Appointment Combination
- NCT07048769 · 246 participants · Phase 4
Paracervical Block for Pain Reduction in Saline Infusion Sonograms
- NCT07176650 · 246 participants · Phase 1
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia